The type 1 insulin-like growth factor receptor pathway

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6364-6370

  Chitnis, Meenali M ^a,b   Yuen, John S P ^a   Protheroe, Andrew S ^b   Pollak, Michael ^c,d   Macaulay, Valentine M ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

A 928605; AMG 479; ANTINEOPLASTIC AGENT; AVE 1642; BIIB 022; BMS 536924; BMS 554417; CP 751871; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IMC A12; INSM 18; MK 0646; OSI 906; PANITUMUMAB; PROTEIN P53; R 1507; SCH 717454; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; XL 228; INSULIN RECEPTOR;

CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; HUMAN; LIGAND BINDING; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOMA; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 56749110996     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4879     Document Type: Review

References (75)

1. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-12.
2. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type1insulin-like growth factorre-ceptor. Cell Mol Life Sci 2000;57:1050-93.
3. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86.
4. Cohen P. The twentieth century struggle to decipher insulin signaling. Nat Rev Mol Cell Biol 2006;7:867-73.
5. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873 -7.
6. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261 -74.
7. Johnson GL, Lapadat R. Mitogen-activated protein kinasepathwaysmediated byERK, JNK, and p38protein kinases. Science 2002;298:1911 -2.
8. Firth SM, Baxter RC. Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 2002;23:824-54.
9. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
10. O'Connor R. Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 2003;35:771-7.
11. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932 -40.
12. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type1 IGF receptor (Igf1r). Cell 1993;75:59-72.
13. Laustsen PG, Russell SJ, Cui L, et al. Essential role of insulin and insulin-like growth factor1 receptor signaling in cardiac development and function. Mol Cell Biol 2007;27:1649 -64.
14. RussoVC, Gluckman PD, Feldman EL,Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005;26:916 -43.
15. Pinkston-GosseJ, Kenyon C. DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans.Nat Genet2007;39:1403-9.
16. Zhang L, Zhou W,Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science1997;276:1268-72.
17. Cui H.Loss of imprinting of IGF2asanepigenetic marker for the risk of human cancer. Dis Markers 2007;23:105-12.
18. Hebert E. Mannose- 6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep 2006;26:7 -17.
19. Sarfstein R, Maor S, Reizner N, Abramovitch S, Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 2006;252:241-6.
20. Yuen JS,Cockman ME, SullivanM,et al. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007;26:6499-508.
21. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phos-phorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
22. ParkerAS, ChevilleJC, JanneyCA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predictpoor survival among women with clear-cell renal cell carcinomas. Hum Pathol 2002;33:801-5.
23. Spentzos D, Cannistra SA, Grall F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer 2007;14:781-90.
24. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryofibroblasts. Mol Cell Biol 1994;14:3604-12.
25. LopezT, Hanahan D. Elevated levels ofIGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002;1:339-53.
26. Jones RA, Campbell CI, Gunther EJ, et al. Transgen-ic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636 -44.
27. Yuen JS, MacaulayVM. Targeting the type1 Insulinlike growth factor receptor as a treatment for cancer. Expert OpinTherTargets 2008;12:589 603.
28. Samani AA,Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
29. Scotlandi K. Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 2006;587:13 -22.
30. Resnicoff M, Coppola D,Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res1994;54:4848-50.
31. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer GeneTher 2005;12:90-100.
32. Lee HY, Chun KH, Liu B, et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002;62:3530-7.
33. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 2006;66:1940-8.
34. Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res1998;58:3353-61.
35. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006;66:362 -71.
36. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11.
37. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8.
38. Yeh AH, Bohula EA, MacaulayVM. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006;25:6574-81.
39. Plymate SR, Haugk K, Coleman I, et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in andro-gen-dependent prostate cancer. Clin Cancer Res 2007;13:6429-39.
40. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulinlike growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells byinhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-93.
41. Trojanek J, HoT, Del Valle L, et al. Role of the insulinlike growth factor I/insulin receptor substrate1 axis in Rad51 trafficking and DNA repair by homologous recombination.Mol Cell Biol 2003;23:7510-24.
42. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
43. Haluska P, Carboni JM,Yu C,et al. HER receptorsig-naling confers resistance to IGF-1R targeted therapy. J. Clin. Oncol. 26: 2008 (May 20 suppl; abstr14510).
44. Lu D, Zhang H, Koo H, et al. A fully human recom-binant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005;280:19665-72.
45. Jerome L, AlamiN,BelangerS,et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 2006;66:7245 -52.
46. Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 2003;35: 778-85.
47. Renehan AG,Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
48. Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007;99:1793-800.
49. Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo antitumor activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulinlike growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007;43:1318-27.
50. Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-23.
51. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1:769-83.
52. Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008;222:9-27.
53. Pan M, Santamaria M,Wollman DB CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Clin Pract Oncol 2007;4:603-7.
54. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391-402.
55. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6:821 -33.
56. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation studyof theanti-insulin-likegrowth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40.
57. Karp DD, Paz-Ares LG, Novello S, et al. High activity of the anti-IGF-1R antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 26: 2008 (May 20 suppl: abstr 8015).
58. Sarantopoulos J, Mita AC, MulayM,et al. AphaseI B study of AMG 479, a type1 insulin-like growth factor receptor (IGF1R) antibody, in combination with pani-tumumab (P) or gemcitabline (G). J Clin Oncol 26:2008 (May 20 suppl; abstr 3583).
59. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, Phar-macokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. JClinOncol2008;26:3196-203.
60. GualbertoA,MelvinCL,DeanA,et al.Characterization of NSLC patients responding to anti-IGF-1R therapy. J Clin Oncol 26: 2008(May20suppl;abstr8000).
61. Tolcher AW, Rothenberg ML, Rodon J, et al. Aphase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I.Vol 25, no18S (June
62. Supplement, 2007:3002).
63. Higano CS,Yu EY,Whiting SH, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin-like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, no 18S (June 20 Supplement), 2007:3505.
64. Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydro-guareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 2008;101:436 -9.
65. Tolcher AW, Patnaik A, Till E, et al. A phase I
66. study of AVE-1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (T). J Clin Oncol 26: 2008 (May 20 suppl; abstr 3582).
67. Olmos D, Okuno S, Schuetze SM, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-1R antibody CP-751,871 in patients with sarcoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 105010).
68. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacody-namic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26:3519.
69. Toretsky JA, Kalebic T, Blakesley V, LeRoith D,
70. Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7.
71. Prieur A, Tirode F, Cohen P, Delattre O. EWS/ FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth
72. factor binding protein 3. Mol Cell Biol 2004;24: 7275-83.
73. GrahamTR, Zhau HE, Odero-Marah VA, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008;68:2479-88.
74. Fuchs BC, Fujii T, Dorfman JD, et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008;68:2391 -9.
75. Weil RJ. Incorporating molecular tools into early-stage clinical trials. PLoS Med 2008;5:e21.